Exeliom Biosciences, a French company focused on the microbiome-immunomodulation axis to develop next-generation immunotherapies, has announced the closing of its €24m (US$26m) Series A financing to advance the clinical development of its therapeutic pipeline, including several clinical trials of EXL01, a novel bacterial immunotherapy with applications in cancer and infectious diseases.
Bergen-based Cytovation ASA has raised US$8m in a Series A extension round to push its cancer compound CyPep-1 into Phase II clinical testing.
,
Belgian T reg specialist Dualyx NV had raised €40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic.
French pancreatic beta-cell modulator specialist DiogenX SA has raised €27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund.
Munich-based microbiome therapeutics specialist mbiomics GmbH has raised €13m in the first closing of Series A round led by MIG Capital.
With assets of €12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market.
Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.
Paris-based AI-inspired drug discovery specialist Iktos SA has closed a €15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.
With Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding.
London-based computer vision specialist V7 Ltd has baged $33m in Series A financing co-led by AI-focused Radical Ventures and Temasek.